SCHEDULE: Nextech Crossover Exits Mersana Therapeutics Stake

Nextech Crossover I GP S.a. r.l. and related entities have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Mersana Therapeutics, Inc. common stock.

Summary

• Nextech Crossover I GP S.a. r.l., Nextech Crossover I SCSp, Ian Charoub, Costas Constantinides, and Rocco Sgobbo (collectively, the "Reporting Persons") have filed an Amendment No. 3 to their Schedule 13G.
• The filing indicates that the Reporting Persons no longer beneficially own any shares of Mersana Therapeutics, Inc. common stock.
• Their aggregate beneficial ownership is now 0.00 shares, representing 0.0% of the class.
• The event requiring this filing occurred on January 6, 2026.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The complete divestment of shares by a group of institutional investors and individuals, reducing their stake to 0%, is a negative signal, suggesting a lack of confidence or a strategic exit from the investment.

Negatives

• Reporting Persons have divested all their beneficial ownership in Mersana Therapeutics, Inc. common stock.
• Their aggregate beneficial ownership has decreased to 0.0% of the class.

Risks

• The complete divestment by Nextech Crossover and its affiliates could be interpreted as a lack of confidence in the issuer's future prospects.

Future Outlook

No forward-looking statements or guidance from Mersana Therapeutics, Inc. are provided in this beneficial ownership filing.

Industry Context

A complete divestment by an institutional investor in the biotechnology sector, such as Nextech Crossover's exit from Mersana Therapeutics, can sometimes signal concerns about the company's clinical pipeline, regulatory hurdles, market positioning, or overall financial health, potentially impacting investor sentiment across the industry.

Stakeholder Impact

• Shareholders: Existing shareholders might view the complete divestment by Nextech Crossover and its affiliates as a negative indicator, potentially leading to downward pressure on the stock price.
• Management: Could face questions regarding the reasons for the institutional exit.

Key Dates

Recommendation

The complete divestment of all beneficial ownership by Nextech Crossover and its associated individuals, reducing their stake to 0.0%, signals a significant loss of confidence or a strategic exit from Mersana Therapeutics. This action by an institutional investor typically warrants a "sell" recommendation or a thorough re-evaluation of the investment, as it suggests underlying concerns about the company's future performance or valuation.

Keywords

Mersana Therapeutics, Nextech Crossover, Schedule 13G, beneficial ownership, common stock, divestment, institutional investor